March 30, 2017 / 11:31 AM / 4 months ago

BRIEF-U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's humira

1 Min Read

March 30 (Reuters) - Abbvie Inc:

* U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information

* U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information

* Abbvie Inc - phase 3 data demonstrate improvement in moderate to severe fingernail psoriasis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below